Immunotherapy for post-transplant lymphoproliferative disease

被引：46

作者：

Straathof, KCM ^{[1
]}

Savoldo, B ^{[1
]}

Heslop, HE ^{[1
]}

Rooney, CM ^{[1
]}

机构：

[1] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA

来源：

关键词：

Epstein-Barr virus; lymphoproliferative disease; transplantation; immunotherapy; cytotoxic T cells;

D O I：

10.1046/j.1365-2141.2002.03594.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：728 / 740

页数：13

共 99 条

[11] CHADBURN A, 1995, AM J PATHOL, V147, P1862
[12] Epstein-Barr virus infection.
Cohen, JI
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (07) : 481 - 492
[13] Infusion of autologous Epstein-Barr virus (EBV) -: specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication
Comoli, P
Labirio, M
Basso, S
Baldanti, F
Grossi, P
Furione, M
Viganò, M
Fiocchi, R
Rossi, G
Ginevri, F
Gridelli, B
Moretta, A
Montagna, D
Locatelli, F
Gerna, G
Comoli, P
[J]. BLOOD, 2002, 99 (07) : 2592 - 2598
[14] Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation
Cook, RC
Connors, JM
Gascoyne, RD
Fradet, G
Levy, RD
[J]. LANCET, 1999, 354 (9191) : 1698 - 1699
[15] Cornelissen JJ, 2000, BLOOD, V96, p507A
[16] Curtis RE, 1999, BLOOD, V94, P2208
[17] DAMORE ESG, 1991, CANCER, V68, P1285, DOI 10.1002/1097-0142(19910915)68:6<1285::AID-CNCR2820680618>3.0.CO
[18] 2-5
[19] Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy
Darenkov, IA
Marcarelli, MA
Basadonna, GP
Friedman, AL
Lorber, KM
Howe, JG
Crouch, J
Crouch, J
Bia, MJ
Kliger, AS
Lorber, MI
[J]. TRANSPLANTATION, 1997, 64 (06) : 848 - 852
[20] Davis C L, 2001, Transpl Infect Dis, V3, P108, DOI 10.1034/j.1399-3062.2001.003002108.x